ArticleLasers in medical science2026
Photoacoustic imaging-based assessment of vascular changes in scars: a retrospective analysis of factors influencing PDL treatment efficacy.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulsed dye laser (PDL) is widely used for hypervascular scars, but real-time evaluation of vascular responses remains limited. Photoacoustic imaging (PAI) enables noninvasive, high-resolution assessment of skin microvasculature. To assess whether PAI can visualize post-PDL vascular changes in real time and identify factors influencing efficacy. This single-center retrospective study analyzed 32 scars treated with 595-nm PDL. Patients were grouped by pulse duration/fluence combination (0.45-6.0 J/cm², 1.5-8.0 J/cm², or 3.0-10.0 J/cm²) or by endpoint (purpuric or nonpurpuric response). PAI, Antera 3D, and Vancouver Scar Scale (VSS) assessments were performed at baseline, immediately after treatment, and 1 month later. PAI enabled real-time, layer-specific visualization of vascular change, a capability that is less readily achievable with the VSS or Antera 3D. No statistically detectable association was identified between the parameter combinations and PDL outcomes. By contrast, the treatment endpoint was significantly associated with vascular outcomes: compared with purpuric treatment, nonpurpuric treatment showed lower adjusted full-dermis vessel density (30.25% vs. 49.29%; difference, - 19.04%; 95% CI, - 28.12 to - 9.97; Holm-adjusted P < 0.001) and smaller vessel diameter (278.74 μm vs. 428.36 μm; ratio, 0.651; 95% CI, 0.500-0.846; Holm-adjusted P = 0.002). Layer-specific outcomes also showed a similar direction of effect. In the exploratory repeated-treatment subset, NPUR was associated with progressive vascular improvement. PAI helps characterize vascular features and may provide additional information to support overall treatment parameter selection. Treatment endpoint was significant correlated to vascular efficacy. PAI suggests that vascular closure without purpura maybe potentially favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.